The annual protocol of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program reports improved overall and recurrence-free survival in patients with highly ER-positive, PR-positive, and AR-positive disease [12]. This evidence concerns the gene AR and breast carcinoma.